S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.42 (-0.29%)
AAPL   139.07 (+1.61%)
MSFT   225.95 (+0.44%)
FB   274.50 (+0.60%)
GOOGL   1,892.56 (+0.45%)
AMZN   3,292.23 (-0.45%)
TSLA   846.64 (+0.20%)
NVDA   548.50 (-1.12%)
BABA   258.62 (-0.53%)
CGC   33.80 (+0.72%)
GE   11.11 (+0.36%)
MU   82.28 (-3.21%)
AMD   92.79 (+1.38%)
NIO   61.95 (+6.19%)
T   28.93 (+0.35%)
F   11.52 (-0.09%)
ACB   10.65 (-4.66%)
BA   205.84 (-0.76%)
DIS   172.78 (+0.88%)
NFLX   565.17 (-2.53%)
GILD   66.94 (-0.06%)
S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.42 (-0.29%)
AAPL   139.07 (+1.61%)
MSFT   225.95 (+0.44%)
FB   274.50 (+0.60%)
GOOGL   1,892.56 (+0.45%)
AMZN   3,292.23 (-0.45%)
TSLA   846.64 (+0.20%)
NVDA   548.50 (-1.12%)
BABA   258.62 (-0.53%)
CGC   33.80 (+0.72%)
GE   11.11 (+0.36%)
MU   82.28 (-3.21%)
AMD   92.79 (+1.38%)
NIO   61.95 (+6.19%)
T   28.93 (+0.35%)
F   11.52 (-0.09%)
ACB   10.65 (-4.66%)
BA   205.84 (-0.76%)
DIS   172.78 (+0.88%)
NFLX   565.17 (-2.53%)
GILD   66.94 (-0.06%)
S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.42 (-0.29%)
AAPL   139.07 (+1.61%)
MSFT   225.95 (+0.44%)
FB   274.50 (+0.60%)
GOOGL   1,892.56 (+0.45%)
AMZN   3,292.23 (-0.45%)
TSLA   846.64 (+0.20%)
NVDA   548.50 (-1.12%)
BABA   258.62 (-0.53%)
CGC   33.80 (+0.72%)
GE   11.11 (+0.36%)
MU   82.28 (-3.21%)
AMD   92.79 (+1.38%)
NIO   61.95 (+6.19%)
T   28.93 (+0.35%)
F   11.52 (-0.09%)
ACB   10.65 (-4.66%)
BA   205.84 (-0.76%)
DIS   172.78 (+0.88%)
NFLX   565.17 (-2.53%)
GILD   66.94 (-0.06%)
S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.42 (-0.29%)
AAPL   139.07 (+1.61%)
MSFT   225.95 (+0.44%)
FB   274.50 (+0.60%)
GOOGL   1,892.56 (+0.45%)
AMZN   3,292.23 (-0.45%)
TSLA   846.64 (+0.20%)
NVDA   548.50 (-1.12%)
BABA   258.62 (-0.53%)
CGC   33.80 (+0.72%)
GE   11.11 (+0.36%)
MU   82.28 (-3.21%)
AMD   92.79 (+1.38%)
NIO   61.95 (+6.19%)
T   28.93 (+0.35%)
F   11.52 (-0.09%)
ACB   10.65 (-4.66%)
BA   205.84 (-0.76%)
DIS   172.78 (+0.88%)
NFLX   565.17 (-2.53%)
GILD   66.94 (-0.06%)
Log in
OTCMKTS:ANTH

Anthera Pharmaceuticals Stock Forecast, Price & News

$0.04
0.00 (0.00 %)
(As of 01/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.04
Now: $0.04▼
$0.04
50-Day Range
$0.02
MA: $0.02▼
$0.05
52-Week Range
$0.01
Now: $0.04▼
$0.06
Volume69,556 shs
Average Volume246,047 shs
Market Capitalization$567,850.00
P/E RatioN/A
Dividend YieldN/A
Beta2.19
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.
Anthera Pharmaceuticals logo

MarketRank™

Overall MarketRank™

0.50 out of 5 stars

Medical Sector

1493rd out of 1,922 stocks

Pharmaceutical Preparations Industry

652nd out of 769 stocks

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ANTH
Previous Symbol
CUSIPN/A
CIK1316175
Webwww.anthera.com
Phone510-856-5600
Employees21

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding Shares13,850,000
Market Cap$567,850.00
Next Earnings DateN/A
OptionableOptionable
$0.04
0.00 (0.00 %)
(As of 01/21/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ANTH News and Ratings via Email

Sign-up to receive the latest news and ratings for ANTH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Anthera Pharmaceuticals (OTCMKTS:ANTH) Frequently Asked Questions

How has Anthera Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Anthera Pharmaceuticals' stock was trading at $0.0292 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ANTH stock has increased by 40.4% and is now trading at $0.0410.
View which stocks have been most impacted by COVID-19.

What stocks does MarketBeat like better than Anthera Pharmaceuticals?

Wall Street analysts have given Anthera Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Anthera Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Anthera Pharmaceuticals' earnings last quarter?

Anthera Pharmaceuticals, Inc. (OTCMKTS:ANTH) posted its quarterly earnings data on Monday, March, 5th. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.82) by $0.09.
View Anthera Pharmaceuticals' earnings history.

When did Anthera Pharmaceuticals' stock split? How did Anthera Pharmaceuticals' stock split work?

Shares of Anthera Pharmaceuticals reverse split before market open on Monday, May 1st 2017. The 1-8 reverse split was announced on Friday, April 28th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 28th 2017. An investor that had 100 shares of Anthera Pharmaceuticals stock prior to the reverse split would have 13 shares after the split.

Who are some of Anthera Pharmaceuticals' key competitors?

Some companies that are related to Anthera Pharmaceuticals include Earth Science Tech (ETST), GlobeImmune (GBIM), VIVUS (VVUSQ), ImmunoCellular Therapeutics (IMUCD), ImmunoCellular Therapeutics (IMUC), Williston (WHCA), Boston Therapeutics (BTHE), Melinta Therapeutics (MLNTQ), VG Life Sciences (VGLS), Cotinga Pharmaceuticals (COTQF), Cardax (CDXI), Inspyr Therapeutics (NSPX), W World (WWHC), TetraLogic Pharmaceuticals (TLOG) and Adhera Therapeutics (ATRX).
View all of ANTH's competitors.

What other stocks do shareholders of Anthera Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anthera Pharmaceuticals investors own include Ocular Therapeutix (OCUL), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Arena Pharmaceuticals (ARNA), OPKO Health (OPK), AVEO Pharmaceuticals (AVEO), Amicus Therapeutics (FOLD) and Alibaba Group (BABA).

Who are Anthera Pharmaceuticals' key executives?

Anthera Pharmaceuticals' management team includes the following people:
  • Mr. Paul F. Truex, Exec. Chairman (Age 52, Pay $100k)
  • Mr. John Craig Thompson, CEO & Director (Age 54, Pay $715.3k)
  • Ms. May Liu, Sr. VP of Fin. & Admin. and Principal Accounting Officer (Age 45)
  • Dr. Paul Adams Ph.D., Sr. VP of Global Regulatory Affairs and Compliance (Age 58)
  • Joshua Caldwell, Chief Liquidating Officer
  • Mr. Bradley A. Bugdanowitz Esq., Sec.
  • Ms. Klara A. Dickinson-Eason, Advisor (Age 53)
  • Dr. Charles V. Olson, Advisor (Age 64)

What is Anthera Pharmaceuticals' stock symbol?

Anthera Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ANTH."

How do I buy shares of Anthera Pharmaceuticals?

Shares of ANTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Anthera Pharmaceuticals' stock price today?

One share of ANTH stock can currently be purchased for approximately $0.04.

How big of a company is Anthera Pharmaceuticals?

Anthera Pharmaceuticals has a market capitalization of $567,850.00. Anthera Pharmaceuticals employs 21 workers across the globe.

What is Anthera Pharmaceuticals' official website?

The official website for Anthera Pharmaceuticals is www.anthera.com.

How can I contact Anthera Pharmaceuticals?

Anthera Pharmaceuticals' mailing address is 25801 INDUSTRIAL BOULEVARD SUITE B, HAYWARD CA, 94545. The biopharmaceutical company can be reached via phone at 510-856-5600.

This page was last updated on 1/22/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.